CareDx, Inc

NASDAQ:CDNA

Medical - Diagnostics & Research

Healthcare
$74.44 +5.07%

+$1.19 today

Market cap
$3.91B
Beta
2.48
P/E (TTM)
-154.0
EPS (TTM)
-$0.16
52W Low $10.96High $24.96

Volume 0.54M

Average 0.74M

CDNA Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

CareDx, IncNASDAQ: CDNA

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow grows, but more slowly than its trailing trend

Q2 FY2026 investing cash flow of $280.59M rose 1099.2% year over year, behind the +3179.5% change in trailing-twelve-month investing cash flow. Sequentially, it rose 2437.2% from the prior quarter.

Context

  • Investing cash flow amounted to 0.6% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +1099.2% toward the trailing-twelve-month pace of +3179.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$280.59M+2437.2% QoQ
Last fiscal yearDec 2025
$2.16M+546.8% YoY
LTMJun 2026
$269.08M+3179.5% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1099.2%——
1 year+546.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
2.16M USD
Year-over-year change
+546.8%
4-year CAGR
-53.9%

Investing Cash Flow vs competitors

How CDNA compares with its peers on the latest reported figures

  • CDNA's LTM Jun 2026 investing cash flow of $269.08M is the largest of the 8 companies compared; the peer median is $38.64M.
  • Its year-over-year change of +3179.5% is the highest of 7, against a peer median of +73.5%.
  • Investing cash flow amounts to 58.7% of revenue for CDNA, versus a peer median of 8.5%.
CDNA Competitors Peer median
Investing Cash Flow for CDNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CDNACareDx, IncLTM Jun 2026$269.08M +3179.5%—58.7%
QGENQiagen N.V.LTM Jun 2026$242.15M +51.6%-25.1%11.5%
NTRANatera, Inc.LTM Jun 2026$187.06M +1913.6%—6.9%
VCYTVeracyte, Inc.LTM Jun 2026$98.67M -9.0%-32.1%17.6%
FLGTFulgent Genetics, Inc.LTM Mar 2026$94.58M +471.0%—29.5%
WGSGeneDx Holdings Corp.LTM Jun 2026$38.64M -28.5%-24.2%8.5%
MYGNMyriad Genetics, Inc.LTM Mar 2026$25.6M +95.4%-29.3%3.1%
BLLNBillionToOne, Inc.LTM Jun 2026$12.22M ——3.1%
Peer median (excluding CDNA) $38.64M+73.5%-27.2%8.5%

Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.66M)(76.61M)(190.28M)52.55M(21.35M)
Depreciation & Amortization11.89M16.01M19.82M19.76M20.42M
Deferred Income Tax00566K(187K)17K
Stock-Based Compensation36.08M46.55M49.09M66.41M34.86M
Change in Working Capital(40.97M)(14.22M)106.03M(102.31M)3.81M
Accounts Receivables(24.42M)(6.66M)16.02M(13.74M)22.52M
Inventory(6.93M)(2.86M)54K(1.02M)(4.96M)
Accounts Payables1.79M(2.05M)2.9M(5.11M)808K
Other Working Capital(11.42M)(2.64M)87.06M(82.44M)(14.56M)
Other Non-Cash Items4.37M3.03M(3.61M)1.83M4.28M
Operating Cash Flow(19.29M)(25.24M)(18.39M)38.05M42.03M
Capital Expenditures(20.26M)(24.33M)(9.24M)(6.48M)(5.91M)
Acquisitions (Net)(15.43M)(610K)(6.68M)00
Purchases of Investments(5.5M)(315.15M)(201.17M)(160.29M)(145.93M)
Sales of Investments88.91M111.59M256.04M166.92M154.67M
Other Investing Activities001.5M(634K)0
Investing Cash Flow47.71M(228.5M)40.45M(483K)2.16M
Debt Repayment(66K)0000
Common Stock Issued188.86M0008M
Common Stock Repurchased0(642K)(27.54M)(522K)(87.77M)
Dividends Paid00000
Other Financing Activities(3.15M)(3.89M)(2.07M)(5.08M)(13.62M)
Financing Cash Flow185.64M(4.54M)(29.61M)(5.61M)(93.39M)
Effect of Forex Changes(303K)23K(112K)532K(90K)
Net Change in Cash213.76M(258.25M)(7.66M)32.49M(49.29M)
Free Cash Flow(39.55M)(49.57M)(27.63M)31.56M36.12M

CareDx, Inc

NASDAQ:CDNA

Intrinsic Alpha fair value

Locked

Current Price

$74.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.